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Introduction 
HIV infection is increasingly becoming a prominent 
cause of  morbidity and mortality with an estimated 
2.5 million people living with HIV in India (1). 
Antiretroviral drugs have dramatically improved the 
quality of  life and increased the life expectancy but 
morphological and metabolic complications of  the 
drugs have threatened to short live this achievement. 
The term Lipodystrophy syndrome was first used to 
describe morphological complications of  these drugs 
in HIV infected adults.  Lipodystrophy syndrome 
encompasses fat redistribution, defined as fat wasting
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of  extremities/ face or buttocks, fat accumulation 
in abdomen or dorsocervical spine (buffalo hump) 
and metabolic complications associated with it- 
dyslipidaemia, insulin resistance(2).
The mechanism responsible for this syndrome remains 
unclear. It has been proposed that antiretroviral drugs such 
as protease inhibitors (PI) and/ or nucleoside analogues 
(stavudine) could contribute to the development of  
such clinical and metabolic abnormalities (2, 6, 13-22, 28-35). 
Various risk factors have been found to be associated 
with the development of  lipodystrophy like older age 
and increasing duration of  treatment (22, 33,34,35).
 Studies have reported complications associated 
with lipodystrophy syndrome viz cardiovascular 
complications (5) and diabetes mellitus type 2 later in 
life. The impact of  fat redistribution and its associated 
metabolic complications on HIV infected children 
is therefore of  obvious concern to paediatricians. 
Various studies have been done worldwide but Indian 
data is very sparse.  Hence we conducted this study 
to assess the prevalence of  fat redistribution and its 
associated risk factors in our tertiary care centre.   
Materials and methods
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Abstract:
Background:  It is estimated that about 2.5 million people are living with HIV infection in India. Although antiretroviral 
drugs have been able to reduce the mortality, these drugs have serious side effects one of  which is lipodystrophy syndrome. 
Most of  the drugs used in HAART viz, protease inhibitors, stavudine and nevirapine are associated with lipodystrophy. 
Hence we conducted this study to assess the prevalence of  lipodystrophy in HIV infected children on HAART and its 
associated risk factors.
Materials and methods:  A cross sectional study was conducted on 80 HIV infected children aged 2-18 years of  age who 
were on stavudine based HAART for ≥2 years. These children were assessed for presence of  lipodystrophy,  its metabolic 
complications and associated risk factors.
Results:  Lipodystrophy was observed in 33.7% of  children with lipoatrophy being the commonest subtype followed by 
lipohypertrophy. Older age, increased duration of  treatment and dyslipidaemia were found to be associated in patients with 
lipodystrophy than those without. On further multivariate analysis of  independent risk factors only increased duration of  
treatment was significantly associated with lipodystrophy. No association was found with insulin resistance.
Conclusion: We observed that lipodystrophy is a common finding in HIV patients treated with HAART for long 
duration. 
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A cross sectional study was conducted over a one 
year period from November 2010 - November 2011 
at a tertiary care centre in northern India. Eighty 
HIV infected children 2-18 years of  age who were 
on Highly Active Antiretroviral Therapy (HAART) 
for a period of  minimum 2 years and who were 
willing to give an informed consent were included in 
the study. Those who had serious or life threatening 
complications of  HIV (active tuberculosis, systemic 
fungal infections, cerebral toxoplasmosis), unwilling 
to give consent, known diabetic, children on steroids 
or lipid lowering drugs and those with congenital 
(SHORT syndrome, Dunnigan syndrome, Kobberling 
syndrome) or acquired (rheumatoid arthritis, SLE) 
causes of  lipodystrophy were excluded. Approval 
was taken from the institutional ethical committee. 
Using the formula for descriptive study (Z²×p×q)/
d²) with the estimated prevalence of  Fat redistribution 
in HIV infected patients (p) = 26%, precision error 
of  estimation (d) = 0.10, and alpha = 0.05, a sample 
size of  at least 75 cases was needed to estimate the 
prevalence
          A detailed history including age, sex, duration 
of  treatment, route of  transmission was taken. WHO 
clinical stage and CD4 count (4) at the time of  enrolment 
for HAART were documented from the patient’s 
clinical records. They were examined for signs of  fat 
redistribution according to the criteria mentioned 
below. Weight and height were measured and BMI 
calculated. To study the metabolic complications 
fasting blood samples were collected for lipid 
profile (serum cholesterol, triglyceride, Low Density 
Lipoprotein (LDL), Very Low Density Lipoprotein 
(VLDL) levels), glucose and insulin levels.. HOMA-IR 
(Homeostasis model assessment of  insulin resistance) 
was calculated as a measure of  insulin resistance.
              Fat redistribution or lipodystrophy was 
assessed by physical examination and divided into 
lipoatrophy, lipohypertrophy and combined subtype. 
Lipoatrophy was considered when sunken cheeks 
with prominent zygomatic arch or thin extremities 
with prominent veins were present with or without 
buttock atrophy. Lipohypertrophy was considered 
when increased abdominal girth or fat accumulation 
‘buffalo hump’ was present. They were considered to 
have fat redistribution if  they had one or more signs. 
One was classed into combined subtype if  one had 
any sign each of  lipoatrophy and lipohypertrophy(2). 
                  Dyslipidaemia was defined as the presence 
of  either hypercholestrolaemia (serum cholesterol ≥ 
200mg/dl) or high LDL (serum LDL ≥130mg/dl) 
or hypertriglyceridaemia (serum triglyceride≥150mg/
dl). Serum cholesterol, triglyceride and LDL were 
measured using the enzymatic colorimetric method 
using Olympus AU400 (2). Insulin resistance was 
measured using HOMA-IR which was calculated 
using the formula HOMA-IR = (fasting glucose (mg/
dl) x insulin µU/dl) / 405. Value of  greater than 3.1 
was considered as insulin resistance (26). Glucose was 
measured using GOD-POD method on Olympus 
AU400. Insulin was measured using ELISA.  
Statistical analysis 
Statistical analysis was performed by the SPSS program 
for Windows, version 17.0. Normally distributed data 
are presented as mean ± SD. Categorical variables 
are presented as absolute numbers and percentage. 
Data were checked for normality before statistical 
analysis using Shaipro Wilk test. Normally distributed 
continuous variables were compared using student’s 
t test. The Mann Whitney U test was used for 
those variables that were not normally distributed. 
Categorical variables were analyzed using the chi 
square test. Multivariate Logistic Regression analysis 
was also used to assess the presence of  risk factors 
with Lipodystrophy.  For all statistical tests, a p value 
less than 0.05 was taken to indicate a significant 
difference.
Results 
A total of  80 HIV infected children with 2 years and 
more of  HAART treatment were recruited. Of  these 
62 (75.5%) were boys. The mean age of  the study 
population was 10.8 ± 3.39 (3-18 years). The median 
time since HAART was first initiated was 4.75 ± 1.49 
(2-7 years) and all patients were on stavudine based 
HAART (stavudine, lamivudine and nevirapine). 
Majority of  patients had acquired the infection 
through vertical transmission (n=68, 85%) followed 
by blood transfusion (n=7, 8.8%) and intravenous 
injection (n=5, 6.2%). At the time of  initiation of  
HAART, majority of  patients had presented with 
loose stools (n=26, 32.5%) followed by asymptomatic 
(n=23, 28.75%), and rest as cough, skin lesions and 
lymphadenopathy. Majority of  patients (n=42, 52.5%) 
were in stage III at the time of  initiation of  HAART 
while (n=25, 31.2%) were in stage I and (n=10, 12.5%) 
and (n=3, 3.8%) were in stage II and IV respectively.
In our population of  80 children, lipodystrophy was 
observed in 27 children with a prevalence of  33.7%. 
All three forms of  fat redistribution was observed of  
which lipoatrophy was commonest (n=18, 66.6%) 
followed by lipohypertrophy (n=3, 11.1%) and 
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combined subtype (n=6, 22.2%). As shown in Table1, 
age and duration of  treatment was significantly higher 
in lipodystrophic group than non lipodystrophic 
patients. 
Table 1.General characteristics and laboratory parameters of  patients with and without lipodystrophy.
Lipodystrophy (n=27)   
mean±SD /  %(n)
Non lipodystrophy(n=53)     
mean±SD /  %(n)
P value
Age 12.48±3.17 9.98±3.157 0.001*
Sex (Male)                    
male: female
70.37%  (19)       
19:8
81.1%  (43)        
43:10
0.27
HAART duration 5.92±0.916 4.264±1.482 <0.001*
WHO stage                       
 I                                       
II                                              
III                                  
IV
 
29.6%                     (8)          
22.2%                     (6)           
 44.4%                   (12)        
3.7%                       (1)
 
32.1%                           (17)      
 7.5%                             (4)        
56.6%                           (30)       
3.8%                              (2)
0.306
CD4 count   
  ≥500 not significant       
350-499 mild      
200-349  advanced      
≤199 severe
48.1%            (13)      
7.4%            (2)      
18.5%       (5)       
25.9%                      (7)
35.8%                  (19)       
22.6%          (12)       
11.3%                           (6)           
30.2%                          (16)
0.288             
0.090            0.377 
0.690
Insulin resistance    
HOMA-IR≥ 3.1 14.8%                     (4) 5.7%                             (6) 0.121
Cholesterol ≥ 200mg/
dl
33.3%                     (9) 5.7%                             (3) 0.002**
LDL≥ 130mg/dl 29.6%                     (8) 9.4%                             (5) 0.021**
TG≥150mg/dl 25.9%                     (7) 5.7%                            (3) 0.026**
*p <0.001, **p<0.05
Similarly hypercholesterolaemia, high LDL levels 
and hypertriglyceridaemia were present in significant 
number of  patients with lipodystrophy than those 
without. Presence of  lipodystrophy did not show any 
association with insulin resistance, particular gender 
or WHO clinical stage and immune status of  the 
patient. 
To explore further, univariate analysis of  the 
association of  risk factors in different subgroups of  
fat redistribution viz, lipoatrophy, lipohypertrophy and 
combined subtype were done. As shown in table 2, 
significant association was found between lipoatrophy 
and increasing duration of  treatment (p value-<0.001) 
and hypertriglyceridaemia (p value-0.026). Combined 
subtype was significantly associated with increasing 
age (p- 0.005), hypercholestrolaemia (p- 0.041) and 
high LDL levels (p- 0.006). Lipohypertrophy was 
observed in those with longer duration of  treatment 
but was not statistically significant.   
Multivariate analysis was performed to further test 
the independent effects of  variables shown to be 
univariably associated with the development of  fat 
redistribution. Only increasing duration of  treatment 
(OR = 2.935, 95%CI - 1.576-5.465 (p value- 0.001)) 
was found to be significantly associated with presence 
of  lipodystrophy.
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Table2. Univariate analysis of  subgroups of  lipodystrophy.
Variable lipoatrophy  (n=18)
mean  ±  SD /  % (n)              
 P value Lipohypertrophy  (n= 3)    
mean  ±  SD /  % (n)              
P 
value
Combined  (n = 6)  
mean  ±  SD /  % (n)              
P value
Present Absent Present Absent Present Absent 
Age 11.94 ± 3.28 10.50 ± 3.34 0.109 11.67 ± 3.21 10.79 ± 
3.38
0.661 14.50 ± 2.26 10.53 ± 3.26 0.005**
Sex (male)     
M:F
72.2%(13)       
2.5:1
79% (49)   
3.5:1 




0.540 66.7% (4)        
2:1
78.4% (58)     
4:1
0.413
Duration 5.89± 0.83 4.52 ± 1.55 <0.001* 6.33 ± 1.15 4.77 ± 
1.52
0.082 5.83 ± 1.17 4.74 ± 1.54 0.094
I n s u l i n 
r e s i s t a n c e 
≥3.1
33.3% (1) 11.7% (9) 0.334 33.3% (1) 11.7% (9) 0.334 33.3% (2) 10.8% (8) 0.161
Cholesterol 
≥ 200mg/dl
27.8% (5) 11.3% (7) 0.085 33.3% (1) 14.3% (11) 0.390 50% (3) 12.2% (9) 0.041**
LDL ≥ 
130mg/dl
22.2% (4) 14.5% (9) 0.475 0% 16.9% (13) 1.000 66.7% (4) 12.2% (9) 0.006**
TG ≥ 
150mg/dl
27.8% (5) 8.1% (5) 0.026** 0% 13%(10) 1.000 33.3% (2) 10.8% (8) 0.161
LDL- low density lipoprotein, TG- triglyceride level, M-male, F- female
*p<0.001, ** p<0.05
Discussion 
The introduction of  HAART as the treatment 
strategy for HIV has improved the life span of  these 
patients but at the cost of  certain fat redistribution 
abnormalities and its metabolic complications. The 
long term concern raised by these abnormalities 
includes cardiovascular complications and diabetes 
mellitus later in life (5) and also decreasing adherence 
to therapy (24). Out of  the various antiretroviral drugs 
used protease inhibitors (PI) especially indinavir has 
been extensively studied as the cause of  lipodystrophy. 
The focus is now shifting towards nucleoside reverse 
transcriptase inhibitors (NRTI) and non nucleoside 
reverse transcriptase inhibitors (NNRTI) especially 
stavudine and nevirapine respectively as these drugs 
are commonly used in developing countries (6, 9, 10). 
Unlike in developed countries where patients receive 
PI based regimens, our patients were treated with 
stavudine, lamivudine and nevirapine. Since these 
changes start appearing within 1 year of  treatment and 
become more apparent in the 2nd year of  treatment 
(8, 10) hence we included those patients who were on 
treatment for more than 2 years. 
Most of  the published studies have patients treated 
with PI based HAART and has reported 1-43% 
prevalence of  lipodystrophy (2, 3, 6, 13-20). Our study is 
one of  those very few studies conducted on stavudine 
based HAART especially in pediatric age group. In 
our study lipodystrophy was observed in 33.7%. Few 
studies on stavudine based HAART have reported a 
prevalence between 27%  - 60.7 %( 8, 22, 28, 29, 30, 33-34). We 
found lipoatrophy as the commonest subtype similar 
to others (8, 11, 12, 20, 21, 33, 34) whereas Aurpibul et al (22) 
reported lipohypertrophy as the commonest subtype.
In our study lipodystrophy was significantly associated 
with older age group and increasing duration of  
treatment. However on multivariate analysis significant 
association was observed only with increasing duration 
of  treatment. This was similar to what was reported 
by Aurpibul et al(22), Kinabo et al(33), Piloya et al(34), 
Innes et al(35) and Griensven et al whereas Pujari et al(8) 
did not find any association with age and duration of  
therapy. 
We did not observe significant association of  
lipodystrophy with CD4 counts, female sex as 
reported by Aurpibul et al (22).  In our experience there 
was significant difference between the lipodystrophy 
group and non lipodystrophy group with regard to 
hypertriglyceridaemia, hypercholestrolaemia and high 
LDL levels and is consistent with that reported by 
Pujari et al(8), Musiime et al(32) and Aurpibul et al(22). 
Piyola et al(35) did not observe any significant difference 
between the two groups with regard to presence of  
dyslipidaemia. Dyslipidaemia was also observed in 
non lipodystrophic group which is similar to findings 
of  Piyola et al(34) and suggest that lipid metabolism 
abnormalities could precede clinical lipodystrophy. 
We did not observe any association of  lipodystrophy 
with insulin resistance.
 NRTIs lead to development of  lipodystrophy by 
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acting on mitochondrial DNA polymerase enzyme and 
leading to mtDNA depletion. Role of  mitochondria in 
adipocytes appear to be more complex and is directed 
towards providing energy for triglyceride synthesis 
and storage. Mitochondrial dysfunction in adipocytes 
limits lipogenesis and lipolysis, and directs metabolism 
towards oxidation while increasing basal glucose uptake. 
Hence the clinical presentation of  fat wasting and 
absence of  dyslipidaemia and insulin resistance with 
NRTI based HAART (23). Despite this fact we observed 
that on univariate analysis, lipoatrophy was significantly 
associated with hypertriglyceridaemia. This was similar 
to observation by Saint Marc et al (11) and Pujari et al (8). In 
our experience few patients also developed mixed type 
of  lipodystrophy which was associated with increasing 
age, hypercholestrolaemia and high LDL. Our finding 
is in sync with the existing literature which states that 
mixed type is more observed in adolescents and it follows 
a gradual and progressive course and in some patients 
lipoatrophy preceeds lipoaccumulation and is associated 
with lipid abnormalities like hypercholestrolaemia and 
hypertriglyceridaemia(27).
The limitation of  this study was the cross section 
study design and limited sample size. Regional analysis 
of  body fat composition by various techniques like 
DEXA(31, 35), bioelectric impedence(25) and measurement 
of  skin fold thickness(32) are more sensitive methods. 
Due to limitation of  resources, subjective method was 
used to assess fat redistribution.  In out tertiary centre, 
HAART with stavudine, lamivudine and nevaripine 
is used as the first line of  treatment. However both 
stavudine and nevirapine individually are known to 
cause lipodystrophy so we could not say clearly which 
of  the drugs was responsible for lipodystrophy in our 
study. Further studies are needed to study the individual 
effects of  these drugs. 
Conclusion 
Lipodystrophy was observed in 33.7% of  the study 
group with lipoatrophy as the commonest subtype. 
Lipodystrophy was significantly associated with 
increasing duration of  treatment. However, no 
association was found with either gender,  W H O 
clinical stage, immune status and insulin resistance. 
On subgroup analysis lipoatrophy was significantly 
associated with increasing duration of  treatment and 
hypertriglyceridaemia. We conclude that lipodystrophy 
is a common finding in HIV infected children on 
HAART. With increased life span thus increasing the 
duration of  treatment, the prevalence of  lipodystrophy 
will increase in future. Regular assessment of  these 
children for lipodystrophy is a must for early corrective 
measures. .  
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